This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) …

This article provides answers and explanations for the key questions about the use of IHC in lung carcinoma diagnosis representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

First, IHC can assist in diagnosis and classification of a neoplasm as a non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), a distinction critically important for determining therapy.

Jan 5, 2015 · Immunohistochemical stains have become invaluable for the diagnosis of pulmonary malignancies (both primary and metastatic), particularly given the small size of transbronchial and endobronchial biopsies and the increasing need to conserve tissue for molecular studies.

The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors.

Sep 1, 2024 · Immunohistochemical (IHC) staining represents a comparatively inexpensive testing method that is attractive as a potential alternative to molecular sequencing methods or fluorescence in situ hybridization for pulmonary biomarker testing.

Apr 4, 2019 · The 2015 World Health Organization Classification of Lung Tumors first introduced the importance of immunohistochemical (IHC) stains as an ancillary test to separate NSCLC subtypes, especially in small biopsy and cytologic samples that constitute most specimens for the diagnosis of lung cancer.

Aug 1, 2024 · Several observations indicate that protein expression analysis by immunohistochemistry (IHC) remains relevant in individuals with non-small-cell lung cancer (NSCLC) when considering targeted therapy, as an early …

Antibodies are widely used in IHC for subtyping NSCLC from small cell lung cancers. Antibodies to NKX2-1 / TTF-1, Napsin A, and surfactant A…

Feb 11, 2019 · The most widely used IHC markers for pulmonary ADC include TTF-1 and Napsin A. TTF-1 is a homeodomain-containing transcription factor that is predominantly found in normal type II alveolar pneumocytes 25 that has shown high sensitivity and specificity in the immunohistochemical labeling of lung adenocarcinomas. 14,18,26,27 TTF-1 is a nuclear ...